A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

@article{Raizer2010API,
  title={A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.},
  author={Jeffrey J. Raizer and Lauren Eileen Abrey and Andrew B. Lassman and Susan M. Chang and Kathleen R. Lamborn and John G. Kuhn and W. K. Alfred Yung and Mark R. Gilbert and Kenneth A Aldape and Patrick Yung Chih Wen and Howard A. Fine and Minesh P. Mehta and Lisa M DeAngelis and Frank Lieberman and Timothy F. Cloughesy and Hillary Robins and Janet E. Dancey and Michael D. Prados},
  journal={Neuro-oncology},
  year={2010},
  volume={12 1},
  pages={95-103}
}
Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 months for NP GBM post-RT. Secondary objectives for recurrent MGs were response, survival, assessment of toxicity, and pharmacokinetics (PKs). Treatment with enzyme-inducing antiepileptic drugs was… CONTINUE READING